User Tools
Sidebar
duke
**This is an old revision of the document!**
Table of Contents
Resources
Class Links
Tuesday Classes
Thursday Classes
Deadlines, CRP 248
Project
Factor XIa Inhibition (Abelacimab) for ECMO and Mechanical Support
- The Drug:
- Abelacimab (a novel Factor XIa inhibitor).
- The Concept:
- A Phase 3 trial evaluating whether a Factor XIa inhibitor reduces circuit thrombosis and bleeding compared to standard unfractionated heparin in patients on mechanical circulatory support.
| date | item |
|---|---|
| 2026-10-27 | LOI for phase II or III trial |
| 2026-12-01 | 10-minute presentation of the LOI |
| 2026-12-08 | take-home exam due |
duke.1790104454.txt.gz · Last modified: by admin
Except where otherwise noted, content on this wiki is licensed under the following license: CC Attribution-Share Alike 4.0 International
